Report Content
Chapter 1 Methodology & Scope
1.1 Industry coverage
1.2 Market scope & definitions
1.3 Base estimates & working
1.3.1 Data collection
1.4 Forecast parameters
1.5 COVID-19 impact at global level
1.6 Data validation
1.7 Data sources
1.7.1 Primary
1.7.2 Secondary
1.7.2.1 Paid sources
1.7.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Tubeless insulin pump industry 3600 synopsis, 2018 – 2032
2.2 Business trends
2.3 Regional trends
2.4 End-use trends
Chapter 3 Tubeless Insulin Pump Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of diabetes
3.2.1.2 Technological advancements in tubeless insulin pump
3.2.1.3 Increasing diabetes care expenditure
3.2.1.4 Injuries caused by conventional & invasive insulin pumps
3.2.1.5 Adoption of facilitative initiatives
3.2.2 Industry pitfalls & challenges
3.2.2.1 High long-term costs associated with tubeless insulin pump
3.2.2.2 Stringent government regulations
3.3 Growth potential analysis
3.3.1 By end-use
3.4 COVID- 19 impact analysis
3.5 Regulatory landscape
3.5.1 U.S.
3.5.2 Europe
3.6 Reimbursement scenario
3.7 Technology landscape
3.8 Incidence & prevalence of diabetes
3.9 Pipeline analysis
3.10 Future market trends
3.11 Gap analysis
3.12 Porter’s analysis
3.13 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Company market share analysis, 2022
4.4 Competitive positioning matrix
4.5 Vendor matrix analysis, 2022
4.6 Strategy dashboard, 2022
Chapter 5 Tubeless Insulin Pump Market Size and Forecast, By End-use (USD Million)
5.1 Key trends, by end-use
5.2 Home care
5.3 Hospitals & clinics
5.4 Others
Chapter 6 Tubeless Insulin Pump Market Size and Forecast, By Region (USD Million)
6.1 Key trends, by region
6.2 North America
6.2.1 U.S.
6.2.2 Canada
6.3 Europe
6.3.1 Germany
6.3.2 UK
6.3.3 France
6.3.4 Spain
6.3.5 Italy
6.4 Asia Pacific
6.4.1 Japan
6.4.2 China
6.4.3 Australia
6.4.4 South Korea
6.5 RoW
Chapter 7 Company Profiles
7.1 Insulet Corporation
7.2 Roche
7.3 Medtrum Technologies
7.4 Terumo Corporation
7.5 Mannkind Corporation
7.6 Terumo Corporation
